



Reyataz[®] (atazanavir) – First-time generic

- On December 27, 2017, [Teva launched](#) an [AB-rated](#) generic version of Bristol-Myers Squibb's [Reyataz \(atazanavir\)](#) 150 mg, 200 mg and 300 mg capsules.
 - Teva was granted 180-days of exclusivity.
- Reyataz is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus infection for patients 3 months and older weighing at least 5 kg.
 - Reyataz is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus.
 - Use of Reyataz/[Norvir[®] \(ritonavir\)](#) in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions.
- Reyataz is also available as an oral powder containing 50 mg/packet; this formulation is not available generically.
- According to IMS data as of October 2017, annual U.S. sales of Reyataz were \$402 million.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.